Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CD19-STAR-T Cells by Bristar Immunotech Biotechnology for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
CD19-STAR-T Cells is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Acute Lymphocytic Leukemia (ALL,...
CD19-STAR-T Cells by China Immunotech for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
CD19-STAR-T Cells is under clinical development by China Immunotech and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute...
CD19-STAR-T Cells by China Immunotech for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
CD19-STAR-T Cells is under clinical development by China Immunotech and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to...